Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Yifan Pharmaceutical Co., Ltd. (002019.SZ)
CNY10.46
+0.27 (+2.65%)
CN SHZ Healthcare Medical - Pharmaceuticals
Address
No. 50, Qinshan 311300
Hangzhou, BJ, CN
Hangzhou, BJ, CN
CEO
Jianguo Guo
Website
yifanyy.com
IPO
2004-07-13
ISIN CNE000001K65
Description
Yifan Pharmaceutical Co., Ltd. engages in the research, development, production, sale of pharmaceutical products, active pharmaceutical ingredients and polymer materials. It provides blood tumors, gynecology, pediatrics, skin, orthopedic drugs, phosphate buffered saline, polyvinyl butyral products, vitamin B5 and original B5. The company was founded on November 10, 2000 and is headquartered in Hangzhou, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY10.46
+0.27 (+2.65%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
14M
Beta
0.57
Float Shares
1.00B
Free Float %
82.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.06% | +1.16% | -6.76% | -21.44% | -13.60% | -12.37% | -20.91% | -34.38% | -47.28% | -34.09% | +752.03% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
10.46
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.00
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%-0.5% Q1'26: -5.4% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+3.1% Q1'26: -41.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-1.4% Q1'26: +5.5% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+9.3% ★ Q1'26: +10.6% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+4.2% Q1'26: +4.2% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+1.0% Q1'26: +17.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×2.55× Q1'26: 3.91× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.43B
est: 2.69B (-9.6%)
|
3.50B
est: 3.15B (+11.1%)
|
4.37B
est: 4.33B (+1.1%)
|
4.63B
est: 4.62B (+0.4%)
|
5.19B
est: 5.26B (-1.4%)
|
5.40B
est: 5.74B (-5.9%)
|
4.41B
est: 4.50B (-2.1%)
|
3.84B
est: 5.27B (-27.2%)
|
4.07B
est: 4.07B (-0.1%)
|
5.16B
est: 5.44B (-5.1%)
|
5.13B
est: 6.10B (-15.9%)
|
5.63B
5.63B – 5.63B
-7.7% YoY
|
6.01B
6.01B – 6.01B
+6.7% YoY
|
6.46B
6.46B – 6.46B
+7.5% YoY
|
| EBITDA |
453.15M
est: 328.11M (+38.1%)
|
1.02B
est: 384.27M (+166.5%)
|
1.69B
est: 527.24M (+221.3%)
|
1.07B
est: 562.28M (+91.1%)
|
1.22B
est: 641.10M (+90.1%)
|
1.19B
est: 699.46M (+70.3%)
|
453.82M
est: 548.75M (-17.3%)
|
379.13M
est: 641.84M (-40.9%)
|
253.66M
est: 496.18M (-48.9%)
|
642.69M
est: 597.51M (+7.6%)
|
825.51M
est: 670.48M (+23.1%)
|
619.05M
619.05M – 619.05M
-7.7% YoY
|
660.48M
660.48M – 660.48M
+6.7% YoY
|
709.71M
709.71M – 709.71M
+7.5% YoY
|
| EBIT |
382.03M
est: 191.45M (+99.5%)
|
936.63M
est: 224.22M (+317.7%)
|
1.59B
est: 307.64M (+416.1%)
|
953.14M
est: 328.08M (+190.5%)
|
1.07B
est: 374.08M (+184.8%)
|
1.01B
est: 408.13M (+148.4%)
|
262.68M
est: 320.19M (-18.0%)
|
171.35M
est: 374.51M (-54.2%)
|
1.09M
est: 289.52M (-99.6%)
|
326.09M
est: 283.36M (+15.1%)
|
476.74M
est: 317.96M (+49.9%)
|
293.57M
293.57M – 293.57M
-7.7% YoY
|
313.22M
313.22M – 313.22M
+6.7% YoY
|
336.57M
336.57M – 336.57M
+7.5% YoY
|
| Net Income |
360.57M
est: 484.87M (-25.6%)
|
704.76M
est: 784.00M (-10.1%)
|
1.31B
est: 1.33B (-1.6%)
|
737.44M
est: 1.01B (-26.8%)
|
903.47M
est: 989.04M (-8.7%)
|
968.39M
est: 1.07B (-9.8%)
|
278.40M
est: 309.58M (-10.1%)
|
191.22M
est: 796.06M (-76.0%)
|
-551.07M
est: -304.55M (-80.9%)
|
385.97M
est: 511.66M (-24.6%)
|
402.02M
est: 609.12M (-34.0%)
|
584.76M
584.76M – 584.76M
-4.0% YoY
|
682.22M
682.22M – 682.22M
+16.7% YoY
|
804.04M
804.04M – 804.04M
+17.9% YoY
|
| SGA |
548.37M
est: 839.82M (-34.7%)
|
749.26M
est: 983.58M (-23.8%)
|
679.34M
est: 1.35B (-49.7%)
|
863.28M
est: 1.44B (-40.0%)
|
1.06B
est: 1.64B (-35.5%)
|
1.11B
est: 1.79B (-37.9%)
|
1.30B
est: 1.40B (-7.7%)
|
1.44B
est: 1.64B (-12.6%)
|
1.50B
est: 1.27B (+18.3%)
|
1.63B
est: 1.70B (-4.3%)
|
1.09B
est: 1.91B (-43.0%)
|
1.76B
1.76B – 1.76B
-7.7% YoY
|
1.88B
1.88B – 1.88B
+6.7% YoY
|
2.02B
2.02B – 2.02B
+7.5% YoY
|
| EPS |
0.33
est: 0.40 (-17.9%)
|
0.64
est: 0.65 (-1.5%)
|
1.15
est: 1.10 (+4.5%)
|
0.61
est: 0.84 (-26.9%)
|
0.75
est: 0.82 (-8.5%)
|
0.80
est: 0.89 (-10.1%)
|
0.23
est: 0.26 (-10.4%)
|
0.16
est: 0.66 (-75.8%)
|
-0.45
est: -0.25 (-78.2%)
|
0.32
est: 0.42 (-23.8%)
|
0.33
est: 0.50 (-34.0%)
|
0.48
0.48 – 0.48
-4.0% YoY
|
0.56
0.56 – 0.56
+16.7% YoY
|
0.66
0.66 – 0.66
+17.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-140.23M
OE per share TTM
-0.12
Owner's Yield
-1.10%
Maintenance CapEx ratio
227.21%
Maint CapEx / Avg PPE
38.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 27 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P China ETF GXC | 0.02% | 99.4K | 0.59% |
| 2 | State Street SPDR S&P Emerging Asia Pacific ETF GMF | 0.01% | 31.3K | 0.49% |
| 3 | Franklin FTSE China ETF FLCH | 0.01% | 19.2K | 0.19% |
| 4 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 98.3K | 0.46% |
| 5 | Franklin FTSE China UCITS ETF FLXC.L | 0.00% | 48.2K | 0.19% |
| 6 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 256.5K | 0.39% |
| 7 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 180.3K | 0.06% |
| 8 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 118.3K | 0.29% |
| 9 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 7.4K | 0.44% |
| 10 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 128.8K | 0.28% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
116.3K
Shares Outstanding
1.22B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dawei Zhang | VP & CFO | — | male |
| Deqi Feng | Board Secretary, Deputy GM, Vice President & Director | — | male |
| Feng Wang | Executive President | — | male |
| Kai Wang | Head of Accounting | — | — |
| William Tan | Director of Sales Team | — | male |
| Xian Feng Cheng | Chairman of the Board of Directors, President & GM | — | male |
| Ximing Li | Deputy GM & Vice President | — | male |
| Xing Lin | Deputy GM, Vice President & Director | — | male |
| Yuhong Geng | Deputy GM & Vice President | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002019.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
